For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- BMS Has High Hopes on Eliquis Follow-Up with Less Bleeding Risks as Patent Loss Looms
July 26, 2022
- Takeda’s Hyqvia Smashes Primary Goal in Global PIII for CIDP
July 25, 2022
- Otsuka Gets EU Panel Backing for Lupus Nephritis Drug
July 25, 2022
- Keytruda, Opdivo, Tagrisso Breach 100 Billion Yen Sales Mark in FY2021: Tally
July 22, 2022
- Daiichi Sankyo Launches Global PII to Test ADC DS-7300 for SCLC
July 22, 2022
- Chugai Enjoys Big Surge in H1 Earnings on Strong Uptake of New Launches
July 22, 2022
- Shionogi to Steadily Promote PIII Trial for COVID Pill after Approval Setback
July 22, 2022
- Gene Therapy VB-111 Fails in PIII Ovarian Cancer Trial: NanoCarrier
July 21, 2022
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Healios to Raise 2.9 Billion Yen for R&D of eNK Cells
July 20, 2022
- Ono Sets Up Venture Capital Unit to Invest in Digital Health
July 20, 2022
- Opdivo Approved in Taiwan for Frontline Esophageal Cancer Use
July 20, 2022
- Enhertu Gets 2nd Line Breast Cancer Nod in Europe: Daiichi Sankyo
July 20, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Konica Minolta’s Cancer Genomic Profiling System Approved in Japan
July 19, 2022
- Kyowa Kirin to Cease Development of Parkinson’s Hopeful KW-6356
July 19, 2022
- Japan Becoming Less Priority Market as Policy Changes Mar Predictability: MSD Exec
July 19, 2022
- Edirol Hits Chinese Market: Chugai
July 19, 2022
- Shionogi COVID Pill Shows Antiviral Activity Against BA.5
July 15, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…